RNA-based Therapeutics Market Size, Share & Trends Analysis Report By Product (Vaccines, Drugs), By Type (mRNA Therapeutics, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotide (ASO) Therapeutics, RNA Aptamer, Other Therapeutics), By Indication (Infectious Diseases, Rare Genetic Diseases/Hereditary Diseases, Oncology, Ophthalmology, Hematological Disorders, Acute Hepatic Porphyria (AHP), Others), By Delivery Mechanism (Lipid Nanoparticles (LNPs), Polymer-Based Nanoparticles, Viral Vectors, Naked RNA), By End User, By Region and By Segment Forecasts, 2025-2034
Global RNA-based Therapeutics Market is valued at USD 12.4 Bn in 2024 and is predicted to reach USD 22.6 Bn by the year 2034 at a 6.5% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
- The growing biopharmaceutical sector, characterized by increased investment and interest in innovative therapies, is propelling the RNA-based therapeutics market.
- The entry of new biotech startups focused on RNA therapeutics is expanding the competitive landscape and driving technological advancements.
- North America dominated the market and accounted for a global revenue share in 2024.
- Ensuring consistent quality and purity of RNA-based products during large-scale production is critical and challenging.
RNA-based therapeutics is a moderately new class of treatment representing significant potential and growth for the treatment of severe and rare diseases. RNA-based therapeutics are gaining significance for several disease targets, such as genetic disorders, HIV, cancer, etc. The growing prevalence of chronic diseases and lack of proper treatment is generating high demand for the development of RNA-based therapeutics. For instance, according to WHO, cancer ranked number two as a cause of death, and about 9.6 million deaths occurred in 2018. Moreover, the rising prevalence of genetic diseases, hematological disorders are generating the global demand for RNA-based therapeutics. Moreover, advancements and development of promising technologies such as SMaRT technology, antisense technology, and RNAi interference technology are expected to generate immense opportunities for the growth of the market in the coming years.
The strong base on ongoing studies for RNA-based therapeutics and the presence of a large number of players investing in the market is estimated to propel the growth of the market significantly over the estimated timeframe. In July 2018, about 320 ongoing clinical studies for RNA-based therapeutics were registered. The introduction of these potential therapies in the coming years is expected to significantly boost the market's overall growth. However, challenges connected with the commercialization of RNA-based therapies such as drug delivery and toxicity may substantially hamper the market growth. Moreover, the high cost of development may hinder the growth of the market. The lack of substitute treatment selections for rare diseases further enhancing the demand for RNA-based therapeutics globally. Additionally, a growing focus of legislative bodies on evolving reimbursement policies is fueling the development of RNA’s molecules process.
Competitive Landscape
Some major key players in the RNA-based Therapeutics Market:
- Biogen Inc.
- TME Pharma
- IVERIC bio (Astellas Pharma)
- Olix Pharmaceuticals
- GlaxoSmithKline Plc
- Sanofi S.A
- Alnylam Pharmaceuticals
- Ionis Pharmaceuticals
- Benitec Biopharma Ltd
- Acuitas Therapeutics
- Arbutus Biopharma
- Silence Therapeutics Plc
- Enzon Pharmaceuticals Inc
- Bio-Path Holdings Inc.
- Calando Pharmaceuticals (Arrowhead Pharmaceuticals Inc.)
- Percheron Therapeutics Limited
- Gene Signal
- Gradalis
- iCo Therapeutics
- Aptose Biosciences
- Viridian Therapeutics, Inc.
- Mirna Therapeutics Inc (Synlogic, Inc.)
- Adhera Therapeutics
- Achieve Life Sciences, Inc.
- Syntara Limited
- Rexahn Pharmaceuticals (Ocuphire Pharma, Inc.)
- Regulus Therapeutics (Novartis)
- Phio Pharmaceuticals Corp.
- Santaris Pharma A/S (Roche)
- Sarepta Therapeutics
- Sirnaomics Inc.
- Dicerna Pharmaceuticals (Novo Nordisk)
- Others
Market Segmentation
The Global RNA-Based Therapeutics Market is segmented based on product, type, indication and end-user. By Product segment, the market is divided into Vaccines and Drugs. Whereas, By Type, the market is categorized into mRNA Therapeutics, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotide (ASO) Therapeutics, RNA Aptamer, and Other Therapeutics. The segmentation includes Indication segment which is further classified into Infectious Diseases, Rare Genetic Diseases/Hereditary Diseases, Oncology, Ophthalmology, Hematological Disorders, Acute Hepatic Porphyria (AHP), and Others. The End User segment comprises Hospitals and Clinics, Research Settings.
Recent Developments:
- In Sept 2024, Ionis Pharmaceuticals, Inc. entered into an agreement with Roche for two early-stage studies, the details of which have not been revealed. These projects prioritize the development of investigational drugs that target RNA and are intended to treat Alzheimer's disease (AD) and Huntington's disease (HD). The firms utilized Ionis' proficiency in identifying pharmaceuticals that specifically addressed the underlying cause of central nervous system ailments while using Roche's extensive worldwide knowledge in the development and marketing of treatments for illnesses of the nervous system.
RNA-based Therapeutics Market Report Scope :
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 12.4 Billion |
| Revenue Forecast In 2034 | USD 22.6 Billion |
| Growth Rate CAGR | CAGR of 6.5% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Mn,and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Product, Type, Indication, End-User and Delivery Mechanism |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; South East Asia |
| Competitive Landscape | Biogen Inc., TME Pharma, IVERIC bio (Astellas Pharma), Olix Pharmaceuticals, GlaxoSmithKline Plc, Sanofi S.A, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Benitec Biopharma Ltd, Acuitas Therapeutics, Arbutus Biopharma, Silence Therapeutics Plc, Enzon Pharmaceuticals Inc, Bio-Path Holdings Inc., Calando Pharmaceuticals (Arrowhead Pharmaceuticals Inc.), Percheron Therapeutics Limited, Gene Signal, Gradalis, iCo Therapeutics, Aptose Biosciences, Viridian Therapeutics, Inc., Mirna Therapeutics Inc (Synlogic, Inc.), Adhera Therapeutics, Achieve Life Sciences, Inc., Syntara Limited, Rexahn Pharmaceuticals (Ocuphire Pharma, Inc.), Regulus Therapeutics (Novartis), Phio Pharmaceuticals Corp., Santaris Pharma A/S (Roche), Sarepta Therapeutics, Sirnaomics Inc., Dicerna Pharmaceuticals (Novo Nordisk), Others |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
RNA-based Therapeutics Market Segmentation:
RNA-based Therapeutics Market by Product-
- Vaccines
- Drugs

RNA-based Therapeutics Market Based on Type-
- mRNA Therapeutics
- RNA Interference (RNAi) Therapeutics
- Antisense Oligonucleotide (ASO) Therapeutics
- RNA Aptamer
- Other Therapeutics
RNA-based Therapeutics Market Based on Indication-
- Infectious Diseases
- Rare Genetic Diseases/Hereditary Diseases
- Oncology
- Ophthalmology
- Hematological Disorders
- Acute Hepatic Porphyria (AHP)
- Others
RNA-based Therapeutics Market Based on End-User-
- Hospitals and Clinics
- Research Settings
RNA-based Therapeutics Market By Delivery Mechanism-
- Lipid Nanoparticles (LNPs)
- Polymer-Based Nanoparticles
- Viral Vectors
- Naked RNA
RNA-based Therapeutics Market Based on Region-
North America-
- The US
- Canada
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
RNA-based Therapeutics Market is valued at USD 12.4 Billion in 2024 and is predicted to reach USD 22.6 Billion by the year 2034
Global RNA-based Therapeutics Market is expected to grow at a 6.5% CAGR during the forecast period for 2025-2034.
RNA-based Therapeutics Market Companies are Biogen Inc., TME Pharma, IVERIC bio (Astellas Pharma), Olix Pharmaceuticals, GlaxoSmithKline Plc, Sanofi S.A, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Benitec Biopharma Ltd, Acuitas Therapeutics, Percheron Therapeutics Limited, Gene Signal, Gradalis, iCo Therapeutics, Aptose Biosciences, Viridian Therapeutics, Inc., Mirna Therapeutics Inc (Synlogic, Inc.), Adhera Therapeutics, Achieve Life Sciences, Inc., Syntara Limited, Rexahn Pharmaceuticals (Ocuphire Pharma, Inc.), Regulus Therapeutics (Novartis), Phio Pharmaceuticals Corp., Santaris Pharma A/S (Roche), Sarepta Therapeutics, Sirnaomics Inc., Dicerna Pharmaceuticals (Novo Nordisk) and Others
Product, Type, Indication, End-User and Delivery Mechanism are the key segments of the RNA-based Therapeutics Market.
North America region is leading the RNA-based Therapeutics Market.